Tatva Chintan Pharma Chem Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/p79sh33vglqaexihdrechusr.pdf

Key Takeaways


SDA: The Demand Shock and Recovery Path

Chintan Shah: "Let us hypothetically assume someone is carrying an inventory of six months and your sales is at 100% levels for which you are maintaining an inventory of 6 months. Now your sales for the Zeolites have dropped to almost 30%. So, your inventory which was hypothetically for six months has gone up to almost 15 months now. So typically, you stop buying the products completely though your business is running at 30%-40% levels."

Non-SDA Portfolio: Growth Engines Firing

Chintan Shah: "This is something exceptional at a rate because this is showing that we were compromising somewhere and now we are giving the full potential. So I would not say that in next financial year again we will see a 60% growth in this PTC particular category."

New Product Pipeline: Commercialization Milestones Stacking Up

Chintan Shah: "We see that these applications for the energy storage systems is now being picked up quite fast and we expect this segment definitely I would not say in this very year or in next year, but we see a very robust future for this particular segment. So, things are moving faster than what we were anticipating."

Margins: Mix, Forex, and Tax Headwinds


Capacity, Capex, and Inventory

Chintan Shah: "Most of the people have been asking me why you are running on such high inventories, but now this is the precise question that you have asked and this is absolutely the reason why we are running on such high inventories all the time because when there is a demand coming in from customers on SDAs it is always coming in larger volumes. So, unless and until you have this inventory you will not be able to take up that opportunity."

Demand Environment by Geography and Segment

Chintan Shah: "Q3 can be a lot better and Q4 will be fully functional as what we have been doing earlier."

Guidance & Commitments

CommitmentSpecificsTimeline
SDA demand recoveryMarginal improvement in Q2; stronger orders already booked for Q3; full normalization from Q4Q2–Q4 FY23
FY23 SDA revenueRoughly 90% of FY22 SDA revenue, with Q3 and Q4 strongly covering upFY23 full year
Non-SDA revenue baseline~₹80 crore/quarter sustained across remaining three quarters; ₹300–320 crore for FY23 from three non-SDA segmentsQ2–Q4 FY23
Dahej capacity expansionCommissioning by end of Q3 FY23, targeting 3,000 metric tons; on schedule despite 21-day construction strikeEnd of Q3 FY23 (November)
Flame retardant plant trialFirst full-scale plant trial starting week of July 25, 2022Q2 FY23 (immediate)
Metal extraction product commercializationFull-scale commercialization after plant trial approvalsDecember 2022/January 2023 (Q4 FY23)
Large SDA customer plant trialFull-scale plant trial confirmed; commercial supplies to followDecember 2022 (trial); FY24 (commercial)
MonoGlyme continuous processPilot trials in Q2 FY23; commercialization ~8–9 months post trialsQ2 FY23 (pilot); ~Q4 FY23/Q1 FY24 (commercial)
Continuous flow intermediate productPilot and full-scale plant operational at DahejEnd of Q3 FY23
Sustainable EBITDA margin22–27% rangeLonger run
Next major capex cycleEnvironmental clearance expected by end of 2023; significant capex likely in 20242024

Key Metrics

MetricQ1 FY23
Revenue from operations₹88.4 cr, decline of 17% YoY vs ₹106.8 cr
EBITDA₹15.2 cr, decline of 42% YoY vs ₹26.3 cr
Operational EBITDA (excl. forex loss)₹20.17 cr, translating to operational EBITDA margin of 23%
EBITDA margin17% vs 25% in Q1 FY22; includes forex loss of ₹4.97 cr
Net profit after tax₹9.8 cr, decline of 58% YoY vs ₹23.1 cr
PAT margin11% vs 22% in Q1 FY22
Exports₹56.4 cr, contributing 64% of total revenue
PTC revenue₹40.3 cr, historically highest quarterly revenue, 46% of total revenue, growth of 79% YoY
PASC revenue₹34.5 cr, 39% of total revenue, growth of 28% YoY
Electrolyte Salts revenue₹6.9 cr, 8% of total revenue; exceeded FY22 full-year revenue of ₹5.68 cr in this quarter alone
SDA revenue₹5.96 cr, 7% of total revenue, decline of 89% YoY; contributed 52% of revenue in Q1 FY22
Non-SDA combined revenue (PTC, Electrolyte Salts, PASC)₹81.8 cr, growth of nearly 60% vs FY22 quarterly average of ₹51.5 cr
SDA demand revival expectationFull demand revival beginning Q4 FY23; marginal improvement in Q2, orders placed for Q3
FY23 SDA revenue guidance~10% reduction vs FY22 (₹224.8 cr in FY22), per management expectation
FY23 non-SDA revenue guidance₹300 to ₹320 cr from PTC, Electrolyte Salts, and PASC combined
Sustainable EBITDA margin range23% to 27%, per management
Tax rate (company level)18% to 20%; Dahej SEZ now at 50% tax holiday (down from 100% in prior years)
Capacity expansion (Dahej SEZ)200 kl additional reaction capability, targeting commissioning by end of Q3 FY23; total capacity ~480 kl post-expansion
Flame retardant plant capacity5,000 metric tons; plant-scale trial beginning in the week of July 25, 2022
IPO proceeds utilized₹83.25 cr out of net proceeds of ₹207.2 cr as of June 30, 2022